牛血漿誘導体市場：誘導体タイプ別、用途別、地域別、2026～2032年

牛血漿誘導体市場の評価、2026～2032年

ワクチンや治療製品における血漿誘導体の使用の増加が、牛血漿誘導体の採用を促進しています。特にスポーツや健康産業において、タンパク質が豊富な栄養補助食品の人気が高まっていることが、市場規模を2024年に19億6,000万米ドルを突破し、2032年には約30億6,000万米ドルの評価額に達する原動力となっています。

これに加えて、動物の健康と栄養に対する意識の高まりが、獣医学における血漿誘導体の需要を支え、牛血漿誘導体の採用に寄与しています。経済成長と発展途上地域での肉の消費量の増加は、2026～2032年までのCAGR 5.70%での市場成長を可能にしています。

牛血漿誘導体市場の定義/概要

牛血漿誘導体は、牛の血漿から抽出される成分であり、細胞を除去した後に残る血液の液体部分です。これらの誘導体には、免疫グロブリン、アルブミン、フィブリノゲンなど様々なタンパク質が含まれ、安全性と有効性を確保するために加工されます。豊富な栄養学的および生物学的特性により、獣医学およびヒト医学の両方において重要な役割を果たしています。

牛血漿誘導体は、様々な分野で多様な用途があります。医療分野では、高タンパク質含有量と生物学的活性により、免疫不全、創傷治癒、外科手術の治療薬として使用されています。食品産業では、プロテインパウダーやスポーツ栄養製剤のような製品において、栄養補助食品や機能性成分として役立っています。さらに農業分野では、血漿誘導体は家畜の成長と免疫力を高めるために家畜飼料に使用されています。

動物用医薬品業界からの需要の増加は、どのように牛血漿誘導体の採用を増加させるか？

免疫不全障害や出血性疾患の有病率の増加は、血漿ベースの治療薬に対する大きな需要を生み出し、牛血漿誘導体市場の主要な促進要因となっています。世界保健機関（WHO）によると、原発性免疫不全症の世界の有病率は2021～2023年の間に28％増加し、血漿誘導体の増産が必要となっています。重要な開発として、Thermo Fisher Scientificは2024年1月に北米全域での牛血漿採取施設の拡張を発表し、Merckは新しい血漿分画技術の導入により生産効率と製品の品質を向上させました。

細胞培養培地やバイオテクノロジー研究における牛血漿誘導体の用途拡大は、もう一つの重要な市場促進要因です。米国国立衛生研究所（National Institutes of Health）の報告によると、牛血漿成分を利用した細胞培養研究の研究費は2023年に35％増加し、8億9,200万米ドルに達します。この動向は業界の大きな動きを促し、SAFC Biosciencesは2024年3月に牛血漿由来の高度な細胞培養サプリメントを発売し、GE Healthcare Life Sciencesはバイオ医薬品生産用の牛由来成長因子のポートフォリオを拡充しました。

動物用医薬品業界からの需要増は、動物ヘルスケアと栄養学への応用の増加により、3番目の重要な推進力となっています。米国農務省は、2023年中に動物用医薬品における牛血漿誘導体の使用量が前年比42%増加することを記録しています。最近の動向としては、Zoetisが2024年2月に血漿をベースとした家畜用栄養補助食品の新シリーズを発表したことや、Boehringer Ingelheim Animal Healthが主要血漿採取企業と戦略的提携を結んだことで、動物用治療薬製造のサプライチェーンが強化されたことなどが挙げられます。

疾病伝播リスクは牛血漿市場の成長を抑制するか？

牛血漿誘導体市場は、その成長を妨げる規制上の課題に直面しています。動物由来製品の収集、加工、使用をめぐる厳しい規制は、しばしば大規模な試験やコンプライアンス対策を必要とします。これはメーカーにとってはコスト増につながり、中小企業にとっては市場参入が制限され、市場全体の拡大に影響を与える可能性があります。

もうひとつの大きな制約は、疾病伝播のリスクです。牛海綿状脳症（BSE）のような人獣共通感染症への懸念は、牛由来製品の使用に対する消費者のためらいにつながる可能性があります。このリスクは厳格な安全プロトコルを必要とし、特に食品安全問題への意識が高まっている地域では、潜在的な購買意欲をそぐ可能性があります。

畜産業の市場変動も牛血漿誘導体の供給に影響を与える可能性があります。疾病の発生、農業慣行の変化、または市場の需要などの要因による牛の個体数の変動は、原料の入手可能性に不安定をもたらす可能性があります。この不安定さは生産計画を妨げ、価格変動につながり、この分野の企業の収益性に影響を与えます。

目次

第1章 イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 市場概要

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 牛血漿誘導体市場：誘導体タイプ別

• 概要
• 免疫グロブリン
• フィブリノーゲン
• 血清アルブミン
• 牛胎児血清
• トロンビン
• 新生仔牛血清

第6章 牛血漿誘導体市場：用途別

• 概要
• 製薬産業
• 診断薬産業
• 細胞培養/バイオテクノロジー
• 研究開発産業
• 食品産業
• 化粧品産業

第7章 牛血漿誘導体市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• CSL Limited
• Grifols S.A.
• Kedrion S.p.A.
• Baxter International, Inc.
• Shire（now part of Takeda）
• Octapharma AG
• Biotest AG
• Fresenius Kabi AG
• LFB Group
• Sangamo Therapeutics, Inc.

第10章 付録

• 関連調査

Bovine Blood Plasma Derivatives Market Valuation - 2026-2032

Increased use of plasma derivatives in vaccines and therapeutic products is propelling the adoption of bovine blood plasma derivatives. The rising popularity of protein-rich nutritional supplements, particularly in sports and health industries is driving the market size to surpass USD 1.96 Billion valued in 2024 to reach a valuation of around USD 3.06 Billion by 2032.

In addition to this, increasing awareness of animal health and nutrition supports the demand for plasma derivatives in veterinary medicine is spurring up the adoption of bovine blood plasma derivatives. Growing economies and increasing meat consumption in developing regions is enabling the market to grow at a CAGR of 5.70% from 2026 to 2032.

Bovine Blood Plasma Derivatives Market: Definition/ Overview

Bovine blood plasma derivatives are components extracted from the blood plasma of cattle, which is the liquid part of blood that remains after cells have been removed. These derivatives include a variety of proteins, such as immunoglobulins, albumin, and fibrinogen, and are often processed to ensure safety and efficacy. They play a significant role in both veterinary and human medicine, owing to their rich nutritional and biological properties.

Bovine blood plasma derivatives have diverse applications across several fields. In the medical sector, they are used in the formulation of therapies for immune deficiencies, wound healing, and surgical applications, thanks to their high protein content and biological activity. In the food industry, they serve as nutritional supplements and functional ingredients in products like protein powders and sports nutrition formulations. Additionally, in agriculture, plasma derivatives are used in animal feed to enhance growth and immunity in livestock.

How will Rising Demand from the Veterinary Pharmaceutical Industry Increase Adoption of Bovine Blood Plasma Derivatives?

The increasing prevalence of immunodeficiency disorders and bleeding conditions has emerged as a primary driver for the bovine blood plasma derivatives market, creating substantial demand for plasma-based therapeutics. According to the World Health Organization, the global prevalence of primary immunodeficiency disorders increased by 28% between 2021 and 2023, necessitating increased production of plasma derivatives. In a significant development, Thermo Fisher Scientific announced in January 2024 its expansion of bovine plasma collection facilities across North America, while Merck's introduction of new plasma fractionation technologies has enhanced production efficiency and product quality.

The growing application of bovine plasma derivatives in cell culture media and biotechnology research represents another crucial market driver. The National Institutes of Health reported that research funding for cell culture studies utilizing bovine plasma components increased by 35% in 2023, reaching USD 892 Million. This trend has prompted major industry movements, with SAFC Biosciences launching an advanced cell culture supplement derived from bovine plasma in March 2024, while GE Healthcare Life Sciences expanded its portfolio of bovine-derived growth factors for biopharmaceutical production.

Rising demand from the veterinary pharmaceutical industry stands as the third significant driver, with increasing applications in animal healthcare and nutrition. The U.S. Department of Agriculture documented a 42% increase in the usage of bovine plasma derivatives in veterinary medicines during 2023 compared to the previous year. Recent developments include Zoetis's February 2024 announcement of a new line of plasma-based nutritional supplements for livestock, while Boehringer Ingelheim Animal Health's strategic partnership with a leading plasma collection company has strengthened its supply chain for veterinary therapeutics production.

Will Risk of Disease Transmission Restrain Bovine Blood Plasma Market Growth?

The bovine blood plasma derivatives market faces regulatory challenges that can hinder its growth. Strict regulations surrounding the collection, processing, and use of animal-derived products often require extensive testing and compliance measures. This can lead to increased costs for manufacturers and may limit market entry for smaller companies, impacting overall market expansion.

Another significant restraint is the risk of disease transmission. Concerns about zoonotic diseases, such as Bovine Spongiform Encephalopathy (BSE), can lead to consumer hesitance regarding the use of bovine-derived products. This risk necessitates rigorous safety protocols and can deter potential buyers, particularly in regions with heightened awareness of food safety issues.

Market fluctuations in the cattle industry can also affect the supply of bovine blood plasma derivatives. Variations in cattle populations due to factors like disease outbreaks, changing agricultural practices, or market demands can create instability in the availability of raw materials. This inconsistency can hinder production planning and lead to price volatility, impacting profitability for companies in the sector.

Category-Wise Acumens

Will Thrombin Segment Dominate in Bovine Blood Plasma Derivatives Market?

The thrombin segment maintains its dominant position in the bovine blood plasma derivatives market, driven by its crucial role in surgical procedures, wound healing, and diagnostic applications. According to the U.S. Food and Drug Administration, thrombin-based products accounted for 45% of all bovine plasma derivative approvals in 2023, highlighting its significant market share. This dominance has spurred major developments, with Pfizer announcing in February 2024 the expansion of its thrombin production facilities in Michigan, while Baxter International launched an advanced thrombin-based surgical sealant featuring enhanced stability and efficacy.

The increasing adoption of thrombin-based hemostatic agents in minimally invasive surgeries has further strengthened its market position. The European Medicines Agency reported a 38% increase in thrombin product usage across surgical procedures between 2022 and 2023. Recent developments include Johnson & Johnson's March 2024 introduction of a novel thrombin delivery system for laparoscopic surgeries, while Takeda Pharmaceutical's acquisition of a specialized plasma derivatives manufacturer has bolstered its thrombin product portfolio.

Which Factors Enhance the Use of Bovine Blood Plasma Derivatives in the Pharmaceutical Industry?

The pharmaceutical industry maintains its leadership in the bovine blood plasma derivatives market, driven by increasing applications in drug development, vaccine production, and therapeutic formulations. According to the U.S. Food and Drug Administration, pharmaceutical applications accounted for 62% of all approved bovine plasma derivative products in 2023, representing a significant market share. This dominance has prompted major developments, with GlaxoSmithKline announcing in January 2024 a $300 million investment in plasma processing facilities, while Novartis expanded its bovine-derived pharmaceutical portfolio through advanced fractionation technologies.

The industry's growth is further fueled by the rising demand for plasma-based vaccines and immunological products. The World Health Organization reported that pharmaceutical companies increased their bovine plasma derivative usage by 43% in 2023 for vaccine development and production. Recent developments include Merck's March 2024 launch of a new plasma-derived growth factor supplement for cell culture applications, while Pfizer's strategic partnership with a leading plasma collection network has strengthened its supply chain for pharmaceutical product development.

Country/Region-wise Acumens

Will Diversity And Vast Workforce in North America Drive Bovine Blood Plasma Derivatives Market Growth?

North America is known to embrace technological advancements leading to early adoption and widespread use of bovine blood plasma derivatives. This is likely to attract a mature ecosystem of established vendors, diverse solutions, and skilled professionals. The higher disposable income and knowledge regarding technological benefits in comparison to other regions is bolstering the application and willingness to invest in Bovine Blood Plasma Derivatives in the organizations located in North America.

Also, the diversity and vast workforce in North America in the prevalent and emerging organizations in industrialized countries like the U.S., Canada are necessitating advanced timekeeping solutions catering to various industries, employee types, and complex work arrangements.

Furthermore, the implementation of strict wage and hour laws along with a strong focus on workplace regulation is driving the demand for accurate and compliant timekeeping solutions to avoid penalties and legal issues. Introduction of well-developed internet infrastructure in tech-savvy environment create a fertile ground for cloud-based solutions and advanced features like biometrics and AI-powered analytics. These innovations are enabling North America dominate the Bovine Blood Plasma Derivatives market during the forecast period.

Will Increasing Research Activities Enhance Adoption of Bovine Blood Plasma Derivatives in Asia Pacific?

The bovine blood plasma derivatives market in Asia Pacific is experiencing remarkable growth, driven by expanding healthcare infrastructure, increasing research activities, and rising demand for plasma-based products across pharmaceutical and biotechnology sectors. According to China's National Medical Products Administration, the regional market for bovine plasma derivatives grew by 38% in 2023, reaching a value of USD 1.5 Billion. This growth trajectory has attracted significant investments, with Samsung Biologics announcing in February 2024 the establishment of a state-of-the-art plasma processing facility in South Korea, while Japan's Takeda Pharmaceutical expanded its presence through a strategic partnership with leading Chinese biotechnology firms.

The region's rapid advancement in biotechnology research and development is fueling market expansion. The Indian Council of Medical Research reported a 45% increase in research projects utilizing bovine plasma derivatives during 2023, with total funding reaching ₹850 crore (USD 103 Million). Recent developments include Thai-based Charoen Pokphand Group's March 2024 launch of Asia's largest bovine plasma collection network, while Singapore's Bio*One Capital invested USD 200 Million in developing advanced plasma fractionation technologies.

Competitive Landscape

The bovine blood plasma derivatives market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the bovine blood plasma derivatives market include:

• CSL Limited
• Grifols S.A.
• Kedrion S.p.A.
• Baxter International, Inc.
• Shire (now part of Takeda)
• Octapharma AG
• Biotest AG
• Fresenius Kabi AG
• LFB Group
• Sangamo Therapeutics, Inc.
• HemaCare Corporation
• Hemex Health
• HemaSource, Inc.
• Proliant Biologicals
• Thermo Fisher Scientific, Inc.
• American Blood Resources Association (ABRA)
• Bovine Blood Products Co.
• Centeon (a part of the LFB Group)
• PPL Therapeutics
• PlasmaLyte

Latest Developments

• In November 2023, Baxalta announced the expansion of its bovine blood plasma derivatives production facility to increase capacity and meet rising global demand for immunoglobulin therapies.
• In September 2023, Grifols launched a new line of bovine-derived albumin products aimed at enhancing patient outcomes in critical care settings, highlighting advancements in product purity and efficacy.

Bovine Blood Plasma Derivatives Market, By Category

• Derivatives Type:
• Immunoglobulin
• Fibrinogen
• Serum Albumin
• Fetal Bovine Serum
• Thrombin
• New Born Calf Serum
• Application:
• Pharmaceutical Industry
• Diagnostics Industry
• Cell Culture/Biotechnology
• Research and Development
• Food Industry
• Cosmetic Industry
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY DERIVATIVES TYPE

• 5.1 Overview
• 5.2 Immunoglobulin
• 5.3 Fibrinogen
• 5.4 Serum Albumin
• 5.5 Fetal Bovine Serum
• 5.6 Thrombin
• 5.7 New Born Calf Serum

6 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Pharmaceutical Industry
• 6.3 Diagnostics Industry
• 6.4 Cell Culture/ Biotechnology
• 6.5 Research and Development
• 6.6 Food Industry
• 6.7 Cosmetic Industry

7 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CSL Limited
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Grifols S.A.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Kedrion S.p.A.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Baxter International, Inc.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Shire (now part of Takeda)
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Octapharma AG
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Biotest AG
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Fresenius Kabi AG
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 LFB Group
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Sangamo Therapeutics, Inc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research